The orthpaedic institute
Neurosurgery
Dr. John C. Stevenson, MD
|
|
Give Review
John Stevenson is an expert in the field of Neurosurgery. He has 3 awards "Meaningful Use Stage 1 Certification", "Eagle Scout" and "Fellow (FAANS)". John C. Stevenson, MD is a published doctor as well. He has 100 publications published. The latest was: Hyperleptinaemia in chronic heart failure. Relationships with insulin. John Stevenson is registered with Medicare and accepts Medicare payments.
Publications
- Effects of weight changes on the bone.
- Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 4. The Million Women Study.
- Primary prevention of cardiovascular disease with HRT.
- HRT and breast cancer risk: a realistic perspective.
- Prevention of osteoporosis: one step forward, two steps back.
- Bisphosphonates and atypical femoral shaft fractures.
- A woman's journey through the reproductive, transitional and postmenopausal periods of life: Impact on cardiovascular and musculo-skeletal risk and the role of estroge...
- Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 3. The Women's Health Initiative: unopposed estrogen.
- Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 2. The Women's Health Initiative: estrogen plus proges...
- Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health.
- Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 1. The Collaborative Reanalysis.
- Aspirin in the primary prevention of cardiovascular disease.
- Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: resul...
- Drug firm conflicting interests. If only WHI was done well.
- Coronary heart disease and menopause management: the swinging pendulum of HRT.
- Type and route of estrogen administration.
- Hormone replacement therapy and cardiovascular disease revisited.
- HRT and cardiovascular disease.
- Adolescent vaccination: coverage achieved by ages 13-15 years, and vaccinations received as recommended during ages 11-12 years, National Health Interview Survey 1997-...
- Non-estrogen-based treatments for menopausal symptoms.
- Primary prevention of coronary heart disease in women.
- Does estrogen therapy reduce coronary artery calcification in postmenopausal women?
- [Management of cardiovascular risk in the peri-menopausal woman--a consensus statement of European cardiologists and gynaecologists].
- Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists.
- HRT and the primary prevention of cardiovascular disease.
- Management of premature menopause.
- Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study.
- HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?
- The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women''s Health Initiative results.
- Which progestogen is more likely to increase the risk of fatal myocardial infarction: a combination of epidemiological and trial evidence.
- A new hormone replacement therapy containing a progestogen with anti-mineralocorticoid activity.
- 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women.
- Managing the menopause: British Menopause Society Council consensus statement on hormone replacement therapy.
- Justification for the use of HRT in the long-term prevention of osteoporosis.
- Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.
- Bone mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate.
- Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome.
- Metabolic effects of hormone replacement therapy.
- Inflammation markers and erythrocyte sedimentation rate but not metabolic syndrome factor score predict coronary heart disease in high socioeconomic class males: the H...
- The metabolic basis for the effects of HRT on coronary heart disease.
- Practical recommendations for hormone replacement therapy in the peri- and postmenopause.
- Termination of the oestrogen-alone arm of the Women''s Health Initiative.
- Where has WHI led us now?
- Erythrocyte-derived measures of membrane lipid composition in healthy men: associations with arachidonic acid at low to moderate but not high insulin sensitivity.
- Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women.
- Managing the menopause: BMS Council Consensus statement on HRT.
- Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers.
- Further confusion in postmenopausal health: new CSM moves on osteoporosis.
- Hormone replacement therapy: review, update, and remaining questions after the Women's Health Initiative Study.
- Breast cancer and HRT: general practice must not pick up the wrong pieces.
- Managing the menopause - British Menopause Society Council consensus statement on hormone replacement therapy.
- Long-term effects of hormone replacement therapy.
- Effects of oestrogen-only and oestrogen-progestogen replacement therapy upon circulating angiotensin I-converting enzyme activity in postmenopausal women.
- On the route to combined evidence from OC and HRT/ERT.
- Effect of postmenopausal oestradiol and dydrogesterone therapy on lipoproteins and insulin sensitivity, secretion and elimination in hysterectomised women.
- Hormone replacement therapy.
- Hormone therapy and heart disease.
- Spotlight on gender.
- Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action?
- The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone.
- 17beta-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women.
- Hormone replacement therapy: where we stand in Europe.
- Coronary heart disease in women.
- Cardiovascular effects of oestrogens.
- Effects of oral and transdermal 17beta-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women.
- Relation of plasma lipids to insulin resistance, nonesterified fatty acid levels, and body fat in men from three ethnic groups: relevance to variation in risk of diabe...
- Maximising the use of HRT: focus on hysterectomised women.
- Non-invasive assessment of vascular function; paradoxical vascular response to intravenous glucose in coronary heart disease.
- Optimising delivery systems for HRT.
- Effects of equine oestrogens on markers of vasoactive function in human coronary artery endothelial cells.
- Management of corticosteroid-induced osteoporosis.
- A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.
- Hyperleptinaemia in chronic heart failure. Relationships with insulin.
- Various actions of oestrogens on the vascular system.
- Use of Pro-Gest cream in postmenopausal women.
- Is there a case for targeting hormone replacement therapy for osteoporosis at the menopause?
- Associations of smoking, alcohol and physical activity with risk factors for coronary heart disease and diabetes in the first follow-up cohort of the Heart Disease and...
- Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk.
- The glycolytic pathway to coronary heart disease: a hypothesis.
- The effect of menopause on serum uric acid levels in non-obese healthy women.
- 17beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells.
- Points to consider for the development of new indications for hormone replacement therapies and estrogen-like molecules. Department of Urogynaecology, King's College H...
- Management of male osteoporosis: report of the UK Consensus Group.
- Factors of the metabolic syndrome: baseline interrelationships in the first follow-up cohort of the HDDRISC Study (HDDRISC-1). Heart Disease and Diabetes Risk Indicato...
- Physiological hyperinsulinemia is not associated with alterations in venous plasma levels of endothelin-1 in healthy individuals.
- Is there a menopausal metabolic syndrome?
- 17 beta-Oestradiol inhibits stimulated endothelin release in human vascular endothelial cells.
- Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure.
- Elevated serum lipoprotein(a) levels in young women with endometriosis.
- Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure.
- Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure.
- Hormone replacement therapy with dydrogesterone and 17 beta-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up.
- DXA longitudinal quality control: a comparison of inbuilt quality assurance, visual inspection, multi-rule Shewhart charts and Cusum analysis.
- Gonadal hormones.
- Evaluation of the European Spine Phantom in a multi-centre clinical trial.
- Metabolic effects of the menopause and oestrogen replacement.
- Transdermal hormone replacement therapy, serum lipids and lipoproteins.
- Postmenopausal hormone replacement therapy and insulin metabolism: effects of route of administration and implications for heart disease and diabetes risk.
- Measuring body fat.
Schools
University Of Glasgow Faculty Of Medicine
University Of Glasgow
Duke University Medical Center
Royal College Of Surgeons England
Procedures Preformed
- Carpal Tunnel Release
- Cerebrospinal Fluid (CSF) Shunt - Insertion, Repair or Removal
- Dural Repair or Other Spinal Spinal Cord Repair
- Herniated Disc Surgery
- View All
Doctors Specialties
- Neurological Spine Surgery
- Neurosurgery
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
- Eagle Scout
- Fellow (FAANS)
Education
-
Duke University Hospital -
University of Glasgow Faculty of Medicine
Drug Facts
| NPI NUMBER | 1780680504 | |
| NPPES Provider LastName | STEVENSON | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 326072245 | |
| NPPES Provider State | FL | |
| Specialty Description | Neurosurgery | |
| Total Claim Count | 1523.0 | |
| Distinct Opioid Count | 8.0 | |
| Opioid Claim Count | 1088.0 | |
| Percent Opioid Claims | 71.44 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1780680504 |
| Last Name Of The Provider | STEVENSON |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
Dr. Brian L. Hoh, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Maryam Rahman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ivan J. Sosa, MD |
|
|
Dr. Anindita Chakraborty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jerzy W. Rokicki, MD |
|
|
Dr. Kristin J. Weaver, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian D. Sindelar, MD
This Doctor is OpenDoctor Recommended.
|